Context Therapeutics director granted 45,000 options
Context Therapeutics Inc. director Luke Nathaniel Walker received a grant of 45,000 stock options to buy Common Stock at an exercise price of $0.576 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Context Therapeutics Inc. director Luke Nathaniel Walker received a grant of 45,000 stock options to buy Common Stock at an exercise price of $0.576 per share. The options vest on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders and expire on June 23, 2036.
Insider Trade Summary
Grant/Award: 45,000 shares
Grant/Award
1 txn
Insider
Walker Luke Nathaniel
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 45,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 45,000 contracts (Direct)
Footnotes (1)
- F1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.
Key Figures
Options granted: 45,000 options
Exercise price: $0.576 per share
Total derivative holdings after grant: 45,000 options
+2 more
5 metrics
Options granted
45,000 options
Stock Option (right to buy) granted to director
Exercise price
$0.576 per share
Conversion or exercise price for Common Stock
Total derivative holdings after grant
45,000 options
Total stock options following this transaction
Vesting date
Earlier of June 24, 2027 or 2027 annual meeting
Vesting condition subject to continued service
Expiration date
June 23, 2036
Option term end date if unexercised
Key Terms
Stock Option (right to buy), exercise price, expiration date, annual meeting of stockholders, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 0.5760"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of stockholders financial
"the Issuer's 2027 annual meeting of stockholders, subject to continued service"
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Context Therapeutics (CNTX) report for Luke Nathaniel Walker?
Context Therapeutics reported a stock option grant to director Luke Nathaniel Walker. He received 45,000 options to buy Common Stock as a compensation award, recorded on a Form 4 insider filing, rather than an open-market stock purchase or sale.
How many Context Therapeutics (CNTX) stock options were granted to the director?
Luke Nathaniel Walker was granted 45,000 stock options. These options give him the right to buy 45,000 shares of Context Therapeutics Common Stock, subject to vesting conditions and a fixed exercise price disclosed in the Form 4 filing.
What is the exercise price and expiration date of the new CNTX stock options?
The granted options have an exercise price of $0.576 per share. They allow the director to buy Context Therapeutics Common Stock at this price and will expire on June 23, 2036 if not exercised before that date.
When do Luke Nathaniel Walker’s Context Therapeutics (CNTX) options vest?
The options vest on the earlier of June 24, 2027 or the 2027 annual meeting. Vesting is also conditioned on his continued service with Context Therapeutics, according to the footnote in the Form 4 filing.
Is the CNTX Form 4 transaction an open-market stock purchase or a compensation grant?
The CNTX Form 4 reflects a compensation-related stock option grant, not an open-market trade. The transaction code “A” and description indicate a grant or award acquisition at a set exercise price, with zero cash paid at grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates